References
- Aldudak, B., et al., 2000. Renal function in pediatric patients with beta-thalassemia major. Pediatric Nephrology, 15(1–2), 109–112.
- Ali, D., Mehran, K., and Moghaddam, A.G., 2008. Comparative evaluation of renal findings in Beta-thalassemia major and intermedia. Saudi Journal of Kidney Diseases and Transplantation, 19(2), 206–209.
- Al-Khabori, M., et al., 2013. Side effects of deferasirox iron chelation in patients with beta thalassemia major or intermedia. Oman Medical Journal, 28(2), 121–124.
- Bagshaw, S.M., and Gibney, R.T.N., 2008. Conventional markers of kidney function. Critical Care Medicine, 36(Suppl), S152–S158.
- Dee, C.M.A., et al., 2014. Incidence of deferasirox-associated renal tubular dysfunction in children and young adults with beta-thalassaemia. British Journal of Haematology, 167(3), 434–436.
- Dou, H., et al., 2019. Effectiveness and safety of deferasirox in thalassemia with iron overload: a meta-analysis. Acta Haematologica, 141(1), 32–42.
- Dubourg, L., et al., 2012. Deferasirox-induced renal impairment in children: an increasing concern for pediatricians. Pediatric Nephrology, 27(11), 2115–2122.
- Economou, M., et al., 2010. Renal dysfunction in patients with beta-thalassemia major receiving iron chelation therapy either with deferoxamine and deferiprone or with deferasirox. Acta Haematologica, 123(3), 148–152.
- Emara, A.M., El Kelany, R.S., and Moustafa, K.A., 2006. Comparative study of the protective effect between deferoxamine and deferiprone on chronic iron overload induced cardiotoxicity in rats. Human & Experimental Toxicology, 25(7), 375–385.
- Faul, F., et al., 2007. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behavior Research Methods, 39(2), 175–191.
- Fisher, S.A., et al., 2013. Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia. The Cochrane Database of Systematic Reviews, (8), CD004450.
- Giardina, P., Rivella, S., et al., 2013. Thalassemia syndromes. In: Hoffman, R. (=eds. Hematology: Basic Principles and Practice. 6th ed. Philadelphia: Elsevier Churchill Livingstone, 505–535.
- Habibi, H., et al., 2019. Synergistic Effect of Simvastatin and Romidepsin on Gamma-globin Gene Induction. Cell Journal, 20(4), 576–583.
- Koliakos, G., et al., 2003. Urine biochemical markers of early renal dysfunction are associated with iron overload in beta-thalassaemia. Clinical and Laboratory Haematology, 25(2), 105–119.
- Malaki, M., et al., 2011. Beta thalassemia major: the effect of age on glomerular filtration rate. Saudi Journal of Kidney Diseases and Transplantation, 22(5), 963–968.
- Martin-Sanchez, D., et al., 2017. Deferasirox-induced iron depletion promotes BclxL downregulation and death of proximal tubular cells. Scientific Reports, 7(1), 41510.
- Musallam, K.M., and Taher, A.T., 2012. Mechanisms of renal disease in β-thalassemia. Journal of the American Society of Nephrology, 23(8), 1299–1302.
- Naderi, M., et al., 2013. A prospective study of tubular dysfunction in pediatric patients with Beta thalassemia major receiving deferasirox. Pediatric Hematology and Oncology, 30(8), 748–754ee.
- Ponticelli, C., et al., 2010. Renal complications in transfusion-dependent beta thalassaemia. Blood Reviews, 24(6), 239–244.
- Safaei-asl, A., et al., 2009. Urine β2 microglobulin and other biochemical indices in β Thalassemia. Acta Med Iran, 47(6), 443–446.
- Sánchez-González, P.D., et al., 2011. Effects of deferasirox on renal function and renal epithelial cell death. Toxicology Letters, 203(2), 154–161.
- Schwartz, G.J., et al., 2009. New equations to estimate GFR in children with CKD. Journal of the American Society of Nephrology, 20(3), 629–637.
- Şen, V., et al., 2015. Urinary early kidney injury molecules in children with beta-thalassemia major. Renal Failure, 37(4), 607–613.
- Sumboonnanonda, A., Sanpakit, K., and Piyaphanee, N., 2009. Renal tubule function in beta-thalassemia after hematopoietic stem cell transplantation. Pediatric Nephrology, 24(1), 183–187.
- Vichinsky, E., 2008. Clinical application of deferasirox: practical patient management. American Journal of Hematology, 83(5), 398–402.
- Waring, W.S., and Moonie, A., 2011. Earlier recognition of nephrotoxicity using novel biomarkers of acute kidney injury. Clinical Toxicology, 49(8), 720–728.